Ocular Histoplasmosis Syndrome

Dean B. Burgess

doi:10.1016/S0161-6420(86)33653-4

Ocular Histoplasmosis Syndrome

Dean B. Burgess

Department of Ophthalmology and Visual Sciences

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The Macular Photocoagulation Study (MPS) is a multi-center clinical trial supported by the National Eye Institute whose purpose is to assess argon laser photocoagulation as a treatment for choroidal neovascular membranes (NVMs) that do not involve the fovea. The MPS documented that in patients with ocular histoplasmosis syndrome argon laser photocoagulation in comparison with no treatment can reduce the risk of severe visual loss from 46 to 13% in the first two years. Accordingly, patients with ocular histoplasmosis and NVMs outside the fovea are advised to undergo prompt treatment with argon laser photocoagulation.

Original language	English
Pages (from-to)	967-968
Number of pages	2
Journal	Ophthalmology
Volume	93
Issue number	7
DOIs	https://doi.org/10.1016/S0161-6420(86)33653-4
State	Published - 1986

Keywords

laser treatment
ocular histoplasmosis
photocoagulation

Access to Document

10.1016/S0161-6420(86)33653-4

Cite this

@article{1a256cc33e534b9eadf853c174abf657,

title = "Ocular Histoplasmosis Syndrome",

abstract = "The Macular Photocoagulation Study (MPS) is a multi-center clinical trial supported by the National Eye Institute whose purpose is to assess argon laser photocoagulation as a treatment for choroidal neovascular membranes (NVMs) that do not involve the fovea. The MPS documented that in patients with ocular histoplasmosis syndrome argon laser photocoagulation in comparison with no treatment can reduce the risk of severe visual loss from 46 to 13% in the first two years. Accordingly, patients with ocular histoplasmosis and NVMs outside the fovea are advised to undergo prompt treatment with argon laser photocoagulation.",

keywords = "laser treatment, ocular histoplasmosis, photocoagulation",

author = "Burgess, {Dean B.}",

year = "1986",

doi = "10.1016/S0161-6420(86)33653-4",

language = "English",

volume = "93",

pages = "967--968",

journal = "Ophthalmology",

issn = "0161-6420",

number = "7",

}

TY - JOUR

T1 - Ocular Histoplasmosis Syndrome

AU - Burgess, Dean B.

PY - 1986

Y1 - 1986

N2 - The Macular Photocoagulation Study (MPS) is a multi-center clinical trial supported by the National Eye Institute whose purpose is to assess argon laser photocoagulation as a treatment for choroidal neovascular membranes (NVMs) that do not involve the fovea. The MPS documented that in patients with ocular histoplasmosis syndrome argon laser photocoagulation in comparison with no treatment can reduce the risk of severe visual loss from 46 to 13% in the first two years. Accordingly, patients with ocular histoplasmosis and NVMs outside the fovea are advised to undergo prompt treatment with argon laser photocoagulation.

AB - The Macular Photocoagulation Study (MPS) is a multi-center clinical trial supported by the National Eye Institute whose purpose is to assess argon laser photocoagulation as a treatment for choroidal neovascular membranes (NVMs) that do not involve the fovea. The MPS documented that in patients with ocular histoplasmosis syndrome argon laser photocoagulation in comparison with no treatment can reduce the risk of severe visual loss from 46 to 13% in the first two years. Accordingly, patients with ocular histoplasmosis and NVMs outside the fovea are advised to undergo prompt treatment with argon laser photocoagulation.

KW - laser treatment

KW - ocular histoplasmosis

KW - photocoagulation

UR - http://www.scopus.com/inward/record.url?scp=0022518459&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(86)33653-4

DO - 10.1016/S0161-6420(86)33653-4

M3 - Article

C2 - 3531956

AN - SCOPUS:0022518459

SN - 0161-6420

VL - 93

SP - 967

EP - 968

JO - Ophthalmology

JF - Ophthalmology

IS - 7

ER -

Ocular Histoplasmosis Syndrome

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this